Increased levels of 2-hydroxyglutarate in AML patients with IDH1-R132H and IDH2-R140Q mutations

European Journal of Haematology

Volumn 85, Issue 5, 2010, Pages 457-459

  Sellner, Leopold ^a   Capper, David ^a   Meyer, Jochen ^a   Langhans, Claus Dieter ^b   Hartog, Christine Maria ^c   Pfeifer, Heike ^c   Serve, Hubert ^c   Ho, Anthony D ^a   Okun, Jürgen G ^a,b   Krämer, Alwin ^a   Von Deimling, Andreas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; 2 OXOGLUTARIC ACID; 3 HYDROXYGLUTAMIC ACID; CITRIC ACID; FLT3 LIGAND; FUMARIC ACID; GLUTARIC ACID; ISOCITRATE DEHYDROGENASE; ISOCITRIC ACID; MIXED LINEAGE LEUKEMIA PROTEIN; NUCLEOPHOSMIN; SUCCINIC ACID; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ASTROCYTOMA; GENE MUTATION; GENE SEQUENCE; GLIOMA CELL; HUMAN; KARYOTYPE; LETTER; MASS FRAGMENTOGRAPHY; OLIGODENDROGLIOMA; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GLUTARATES; HUMANS; ISOCITRATE DEHYDROGENASE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION, MISSENSE;

EID: 77958534745     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01505.x     Document Type: Letter

References (11)

1. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909-18.
2. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009;361:1058-66.
3. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, Von DA. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008;116:597-602.
4. Abdel-Wahab O, Manshouri T, Patel J, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010;70:447-52.
5. Chou WC, Hou HA, Chen CY, et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood 2010;115:2749-54.
6. Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 2010;362:369-70.
7. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010;17:225-34.
8. Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010;28:2348-55.
9. Wagner K, Damm F, Gohring G, et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 2010;28:2356-64.
10. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739-44.
11. Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010;207:339-44.